nodes	percent_of_prediction	percent_of_DWPC	metapath
Zuclopenthixol—Urinary tract disorder—Etoposide—muscle cancer	0.00401	0.00401	CcSEcCtD
Zuclopenthixol—Agitation—Vincristine—muscle cancer	0.00401	0.00401	CcSEcCtD
Zuclopenthixol—Polyuria—Methotrexate—muscle cancer	0.004	0.004	CcSEcCtD
Zuclopenthixol—Urethral disorder—Etoposide—muscle cancer	0.00398	0.00398	CcSEcCtD
Zuclopenthixol—Vertigo—Vincristine—muscle cancer	0.00392	0.00392	CcSEcCtD
Zuclopenthixol—Leukopenia—Vincristine—muscle cancer	0.0039	0.0039	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Dactinomycin—muscle cancer	0.0039	0.0039	CcSEcCtD
Zuclopenthixol—Anorexia—Dactinomycin—muscle cancer	0.0038	0.0038	CcSEcCtD
Zuclopenthixol—Eye disorder—Etoposide—muscle cancer	0.00379	0.00379	CcSEcCtD
Zuclopenthixol—Convulsion—Vincristine—muscle cancer	0.00378	0.00378	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Etoposide—muscle cancer	0.00376	0.00376	CcSEcCtD
Zuclopenthixol—Hypertension—Vincristine—muscle cancer	0.00376	0.00376	CcSEcCtD
Zuclopenthixol—Myalgia—Vincristine—muscle cancer	0.00371	0.00371	CcSEcCtD
Zuclopenthixol—Angiopathy—Etoposide—muscle cancer	0.00368	0.00368	CcSEcCtD
Zuclopenthixol—Hypertonia—Doxorubicin—muscle cancer	0.00367	0.00367	CcSEcCtD
Zuclopenthixol—Immune system disorder—Etoposide—muscle cancer	0.00366	0.00366	CcSEcCtD
Zuclopenthixol—Abnormal vision—Doxorubicin—muscle cancer	0.00365	0.00365	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.00363	0.00363	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Vincristine—muscle cancer	0.00356	0.00356	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Vincristine—muscle cancer	0.00349	0.00349	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Vincristine—muscle cancer	0.00348	0.00348	CcSEcCtD
Zuclopenthixol—Decreased appetite—Dactinomycin—muscle cancer	0.00346	0.00346	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Vincristine—muscle cancer	0.00344	0.00344	CcSEcCtD
Zuclopenthixol—Fatigue—Dactinomycin—muscle cancer	0.00343	0.00343	CcSEcCtD
Zuclopenthixol—Pain—Dactinomycin—muscle cancer	0.00341	0.00341	CcSEcCtD
Zuclopenthixol—Vascular purpura—Doxorubicin—muscle cancer	0.0034	0.0034	CcSEcCtD
Zuclopenthixol—Anorexia—Vincristine—muscle cancer	0.00339	0.00339	CcSEcCtD
Zuclopenthixol—Hypotension—Vincristine—muscle cancer	0.00332	0.00332	CcSEcCtD
Zuclopenthixol—Ataxia—Methotrexate—muscle cancer	0.0033	0.0033	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Dactinomycin—muscle cancer	0.00328	0.00328	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Etoposide—muscle cancer	0.00328	0.00328	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Dactinomycin—muscle cancer	0.00326	0.00326	CcSEcCtD
Zuclopenthixol—Hot flush—Doxorubicin—muscle cancer	0.00325	0.00325	CcSEcCtD
Zuclopenthixol—Liver function test abnormal—Methotrexate—muscle cancer	0.00324	0.00324	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Vincristine—muscle cancer	0.00324	0.00324	CcSEcCtD
Zuclopenthixol—Increased appetite—Doxorubicin—muscle cancer	0.00324	0.00324	CcSEcCtD
Zuclopenthixol—Menopausal symptoms—Doxorubicin—muscle cancer	0.00322	0.00322	CcSEcCtD
Zuclopenthixol—Insomnia—Vincristine—muscle cancer	0.00322	0.00322	CcSEcCtD
Zuclopenthixol—Paraesthesia—Vincristine—muscle cancer	0.00319	0.00319	CcSEcCtD
Zuclopenthixol—Malaise—Etoposide—muscle cancer	0.00318	0.00318	CcSEcCtD
Zuclopenthixol—Breast disorder—Methotrexate—muscle cancer	0.00317	0.00317	CcSEcCtD
Zuclopenthixol—Vertigo—Etoposide—muscle cancer	0.00317	0.00317	CcSEcCtD
Zuclopenthixol—Leukopenia—Etoposide—muscle cancer	0.00316	0.00316	CcSEcCtD
Zuclopenthixol—Purpura—Doxorubicin—muscle cancer	0.00316	0.00316	CcSEcCtD
Zuclopenthixol—Body temperature increased—Dactinomycin—muscle cancer	0.00315	0.00315	CcSEcCtD
Zuclopenthixol—Abdominal pain—Dactinomycin—muscle cancer	0.00315	0.00315	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Etoposide—muscle cancer	0.0031	0.0031	CcSEcCtD
Zuclopenthixol—Decreased appetite—Vincristine—muscle cancer	0.00309	0.00309	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Vincristine—muscle cancer	0.00307	0.00307	CcSEcCtD
Zuclopenthixol—Fatigue—Vincristine—muscle cancer	0.00307	0.00307	CcSEcCtD
Zuclopenthixol—Convulsion—Etoposide—muscle cancer	0.00306	0.00306	CcSEcCtD
Zuclopenthixol—Hypertension—Etoposide—muscle cancer	0.00305	0.00305	CcSEcCtD
Zuclopenthixol—Pain—Vincristine—muscle cancer	0.00304	0.00304	CcSEcCtD
Zuclopenthixol—Constipation—Vincristine—muscle cancer	0.00304	0.00304	CcSEcCtD
Zuclopenthixol—Eosinophilia—Methotrexate—muscle cancer	0.00301	0.00301	CcSEcCtD
Zuclopenthixol—Migraine—Doxorubicin—muscle cancer	0.00299	0.00299	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.00299	0.00299	CcSEcCtD
Zuclopenthixol—Discomfort—Etoposide—muscle cancer	0.00297	0.00297	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Dactinomycin—muscle cancer	0.00293	0.00293	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Vincristine—muscle cancer	0.00291	0.00291	CcSEcCtD
Zuclopenthixol—Pancytopenia—Methotrexate—muscle cancer	0.00288	0.00288	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Etoposide—muscle cancer	0.00288	0.00288	CcSEcCtD
Zuclopenthixol—Ataxia—Doxorubicin—muscle cancer	0.00286	0.00286	CcSEcCtD
Zuclopenthixol—Asthenia—Dactinomycin—muscle cancer	0.00286	0.00286	CcSEcCtD
Zuclopenthixol—Dysuria—Methotrexate—muscle cancer	0.00284	0.00284	CcSEcCtD
Zuclopenthixol—Neutropenia—Methotrexate—muscle cancer	0.00284	0.00284	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Etoposide—muscle cancer	0.00282	0.00282	CcSEcCtD
Zuclopenthixol—Tachycardia—Etoposide—muscle cancer	0.00281	0.00281	CcSEcCtD
Zuclopenthixol—Body temperature increased—Vincristine—muscle cancer	0.00281	0.00281	CcSEcCtD
Zuclopenthixol—Abdominal pain—Vincristine—muscle cancer	0.00281	0.00281	CcSEcCtD
Zuclopenthixol—Liver function test abnormal—Doxorubicin—muscle cancer	0.00281	0.00281	CcSEcCtD
Zuclopenthixol—Skin disorder—Etoposide—muscle cancer	0.0028	0.0028	CcSEcCtD
Zuclopenthixol—Erectile dysfunction—Methotrexate—muscle cancer	0.0028	0.0028	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Etoposide—muscle cancer	0.00279	0.00279	CcSEcCtD
Zuclopenthixol—Photosensitivity reaction—Methotrexate—muscle cancer	0.00277	0.00277	CcSEcCtD
Zuclopenthixol—Breast disorder—Doxorubicin—muscle cancer	0.00275	0.00275	CcSEcCtD
Zuclopenthixol—Anorexia—Etoposide—muscle cancer	0.00275	0.00275	CcSEcCtD
Zuclopenthixol—Diarrhoea—Dactinomycin—muscle cancer	0.00272	0.00272	CcSEcCtD
Zuclopenthixol—Nasopharyngitis—Doxorubicin—muscle cancer	0.00272	0.00272	CcSEcCtD
Zuclopenthixol—Drowsiness—Methotrexate—muscle cancer	0.00271	0.00271	CcSEcCtD
Zuclopenthixol—Hypotension—Etoposide—muscle cancer	0.00269	0.00269	CcSEcCtD
Zuclopenthixol—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.00268	0.00268	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Vincristine—muscle cancer	0.00262	0.00262	CcSEcCtD
Zuclopenthixol—Eosinophilia—Doxorubicin—muscle cancer	0.0026	0.0026	CcSEcCtD
Zuclopenthixol—Sweating—Methotrexate—muscle cancer	0.00259	0.00259	CcSEcCtD
Zuclopenthixol—Paraesthesia—Etoposide—muscle cancer	0.00259	0.00259	CcSEcCtD
Zuclopenthixol—Dyspnoea—Etoposide—muscle cancer	0.00257	0.00257	CcSEcCtD
Zuclopenthixol—Somnolence—Etoposide—muscle cancer	0.00256	0.00256	CcSEcCtD
Zuclopenthixol—Hepatobiliary disease—Methotrexate—muscle cancer	0.00256	0.00256	CcSEcCtD
Zuclopenthixol—Asthenia—Vincristine—muscle cancer	0.00255	0.00255	CcSEcCtD
Zuclopenthixol—Vomiting—Dactinomycin—muscle cancer	0.00253	0.00253	CcSEcCtD
Zuclopenthixol—Agranulocytosis—Methotrexate—muscle cancer	0.00253	0.00253	CcSEcCtD
Zuclopenthixol—Rash—Dactinomycin—muscle cancer	0.00251	0.00251	CcSEcCtD
Zuclopenthixol—Decreased appetite—Etoposide—muscle cancer	0.00251	0.00251	CcSEcCtD
Zuclopenthixol—Pancytopenia—Doxorubicin—muscle cancer	0.0025	0.0025	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Etoposide—muscle cancer	0.00249	0.00249	CcSEcCtD
Zuclopenthixol—Fatigue—Etoposide—muscle cancer	0.00248	0.00248	CcSEcCtD
Zuclopenthixol—Pain—Etoposide—muscle cancer	0.00246	0.00246	CcSEcCtD
Zuclopenthixol—Constipation—Etoposide—muscle cancer	0.00246	0.00246	CcSEcCtD
Zuclopenthixol—Dysuria—Doxorubicin—muscle cancer	0.00246	0.00246	CcSEcCtD
Zuclopenthixol—Neutropenia—Doxorubicin—muscle cancer	0.00246	0.00246	CcSEcCtD
Zuclopenthixol—Diarrhoea—Vincristine—muscle cancer	0.00243	0.00243	CcSEcCtD
Zuclopenthixol—Urinary tract disorder—Methotrexate—muscle cancer	0.0024	0.0024	CcSEcCtD
Zuclopenthixol—Photosensitivity reaction—Doxorubicin—muscle cancer	0.0024	0.0024	CcSEcCtD
Zuclopenthixol—Weight increased—Doxorubicin—muscle cancer	0.00239	0.00239	CcSEcCtD
Zuclopenthixol—Urethral disorder—Methotrexate—muscle cancer	0.00238	0.00238	CcSEcCtD
Zuclopenthixol—Weight decreased—Doxorubicin—muscle cancer	0.00238	0.00238	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Etoposide—muscle cancer	0.00238	0.00238	CcSEcCtD
Zuclopenthixol—Hyperglycaemia—Doxorubicin—muscle cancer	0.00237	0.00237	CcSEcCtD
Zuclopenthixol—Nausea—Dactinomycin—muscle cancer	0.00237	0.00237	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Etoposide—muscle cancer	0.00236	0.00236	CcSEcCtD
Zuclopenthixol—Dizziness—Vincristine—muscle cancer	0.00235	0.00235	CcSEcCtD
Zuclopenthixol—Drowsiness—Doxorubicin—muscle cancer	0.00234	0.00234	CcSEcCtD
Zuclopenthixol—Visual impairment—Methotrexate—muscle cancer	0.00234	0.00234	CcSEcCtD
Zuclopenthixol—Jaundice—Doxorubicin—muscle cancer	0.00228	0.00228	CcSEcCtD
Zuclopenthixol—Abdominal pain—Etoposide—muscle cancer	0.00228	0.00228	CcSEcCtD
Zuclopenthixol—Body temperature increased—Etoposide—muscle cancer	0.00228	0.00228	CcSEcCtD
Zuclopenthixol—Eye disorder—Methotrexate—muscle cancer	0.00227	0.00227	CcSEcCtD
Zuclopenthixol—Tinnitus—Methotrexate—muscle cancer	0.00227	0.00227	CcSEcCtD
Zuclopenthixol—Vomiting—Vincristine—muscle cancer	0.00226	0.00226	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Methotrexate—muscle cancer	0.00226	0.00226	CcSEcCtD
Zuclopenthixol—Sweating—Doxorubicin—muscle cancer	0.00225	0.00225	CcSEcCtD
Zuclopenthixol—Rash—Vincristine—muscle cancer	0.00224	0.00224	CcSEcCtD
Zuclopenthixol—Dermatitis—Vincristine—muscle cancer	0.00224	0.00224	CcSEcCtD
Zuclopenthixol—Headache—Vincristine—muscle cancer	0.00223	0.00223	CcSEcCtD
Zuclopenthixol—Hepatobiliary disease—Doxorubicin—muscle cancer	0.00222	0.00222	CcSEcCtD
Zuclopenthixol—Angiopathy—Methotrexate—muscle cancer	0.0022	0.0022	CcSEcCtD
Zuclopenthixol—Immune system disorder—Methotrexate—muscle cancer	0.00219	0.00219	CcSEcCtD
Zuclopenthixol—Agranulocytosis—Doxorubicin—muscle cancer	0.00219	0.00219	CcSEcCtD
Zuclopenthixol—Mental disorder—Methotrexate—muscle cancer	0.00213	0.00213	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Etoposide—muscle cancer	0.00212	0.00212	CcSEcCtD
Zuclopenthixol—Erythema—Methotrexate—muscle cancer	0.00212	0.00212	CcSEcCtD
Zuclopenthixol—Malnutrition—Methotrexate—muscle cancer	0.00212	0.00212	CcSEcCtD
Zuclopenthixol—Nausea—Vincristine—muscle cancer	0.00211	0.00211	CcSEcCtD
Zuclopenthixol—Urinary tract disorder—Doxorubicin—muscle cancer	0.00208	0.00208	CcSEcCtD
Zuclopenthixol—Oedema peripheral—Doxorubicin—muscle cancer	0.00207	0.00207	CcSEcCtD
Zuclopenthixol—Asthenia—Etoposide—muscle cancer	0.00207	0.00207	CcSEcCtD
Zuclopenthixol—Connective tissue disorder—Doxorubicin—muscle cancer	0.00207	0.00207	CcSEcCtD
Zuclopenthixol—Urethral disorder—Doxorubicin—muscle cancer	0.00206	0.00206	CcSEcCtD
Zuclopenthixol—Pruritus—Etoposide—muscle cancer	0.00204	0.00204	CcSEcCtD
Zuclopenthixol—Visual impairment—Doxorubicin—muscle cancer	0.00203	0.00203	CcSEcCtD
Zuclopenthixol—Vision blurred—Methotrexate—muscle cancer	0.00199	0.00199	CcSEcCtD
Zuclopenthixol—Diarrhoea—Etoposide—muscle cancer	0.00197	0.00197	CcSEcCtD
Zuclopenthixol—Eye disorder—Doxorubicin—muscle cancer	0.00197	0.00197	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Methotrexate—muscle cancer	0.00196	0.00196	CcSEcCtD
Zuclopenthixol—Tinnitus—Doxorubicin—muscle cancer	0.00196	0.00196	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Doxorubicin—muscle cancer	0.00195	0.00195	CcSEcCtD
Zuclopenthixol—Angiopathy—Doxorubicin—muscle cancer	0.00191	0.00191	CcSEcCtD
Zuclopenthixol—Malaise—Methotrexate—muscle cancer	0.00191	0.00191	CcSEcCtD
Zuclopenthixol—Dizziness—Etoposide—muscle cancer	0.00191	0.00191	CcSEcCtD
Zuclopenthixol—Immune system disorder—Doxorubicin—muscle cancer	0.0019	0.0019	CcSEcCtD
Zuclopenthixol—Vertigo—Methotrexate—muscle cancer	0.0019	0.0019	CcSEcCtD
Zuclopenthixol—Leukopenia—Methotrexate—muscle cancer	0.00189	0.00189	CcSEcCtD
Zuclopenthixol—Arrhythmia—Doxorubicin—muscle cancer	0.00188	0.00188	CcSEcCtD
Zuclopenthixol—Mental disorder—Doxorubicin—muscle cancer	0.00184	0.00184	CcSEcCtD
Zuclopenthixol—Convulsion—Methotrexate—muscle cancer	0.00183	0.00183	CcSEcCtD
Zuclopenthixol—Vomiting—Etoposide—muscle cancer	0.00183	0.00183	CcSEcCtD
Zuclopenthixol—Erythema—Doxorubicin—muscle cancer	0.00183	0.00183	CcSEcCtD
Zuclopenthixol—Malnutrition—Doxorubicin—muscle cancer	0.00183	0.00183	CcSEcCtD
Zuclopenthixol—Rash—Etoposide—muscle cancer	0.00182	0.00182	CcSEcCtD
Zuclopenthixol—Dermatitis—Etoposide—muscle cancer	0.00182	0.00182	CcSEcCtD
Zuclopenthixol—Headache—Etoposide—muscle cancer	0.00181	0.00181	CcSEcCtD
Zuclopenthixol—Flatulence—Doxorubicin—muscle cancer	0.0018	0.0018	CcSEcCtD
Zuclopenthixol—Myalgia—Methotrexate—muscle cancer	0.0018	0.0018	CcSEcCtD
Zuclopenthixol—Tension—Doxorubicin—muscle cancer	0.0018	0.0018	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.00179	0.00179	CcSEcCtD
Zuclopenthixol—Discomfort—Methotrexate—muscle cancer	0.00178	0.00178	CcSEcCtD
Zuclopenthixol—Nervousness—Doxorubicin—muscle cancer	0.00178	0.00178	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Methotrexate—muscle cancer	0.00173	0.00173	CcSEcCtD
Zuclopenthixol—Vision blurred—Doxorubicin—muscle cancer	0.00173	0.00173	CcSEcCtD
Zuclopenthixol—Nausea—Etoposide—muscle cancer	0.00171	0.00171	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Doxorubicin—muscle cancer	0.0017	0.0017	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Methotrexate—muscle cancer	0.00169	0.00169	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Methotrexate—muscle cancer	0.00169	0.00169	CcSEcCtD
Zuclopenthixol—Agitation—Doxorubicin—muscle cancer	0.00168	0.00168	CcSEcCtD
Zuclopenthixol—Skin disorder—Methotrexate—muscle cancer	0.00168	0.00168	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Methotrexate—muscle cancer	0.00167	0.00167	CcSEcCtD
Zuclopenthixol—Malaise—Doxorubicin—muscle cancer	0.00165	0.00165	CcSEcCtD
Zuclopenthixol—Vertigo—Doxorubicin—muscle cancer	0.00165	0.00165	CcSEcCtD
Zuclopenthixol—Anorexia—Methotrexate—muscle cancer	0.00165	0.00165	CcSEcCtD
Zuclopenthixol—Syncope—Doxorubicin—muscle cancer	0.00164	0.00164	CcSEcCtD
Zuclopenthixol—Leukopenia—Doxorubicin—muscle cancer	0.00164	0.00164	CcSEcCtD
Zuclopenthixol—Palpitations—Doxorubicin—muscle cancer	0.00162	0.00162	CcSEcCtD
Zuclopenthixol—Hypotension—Methotrexate—muscle cancer	0.00161	0.00161	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Doxorubicin—muscle cancer	0.00161	0.00161	CcSEcCtD
Zuclopenthixol—Convulsion—Doxorubicin—muscle cancer	0.00159	0.00159	CcSEcCtD
Zuclopenthixol—Hypertension—Doxorubicin—muscle cancer	0.00158	0.00158	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.00157	0.00157	CcSEcCtD
Zuclopenthixol—Insomnia—Methotrexate—muscle cancer	0.00156	0.00156	CcSEcCtD
Zuclopenthixol—Myalgia—Doxorubicin—muscle cancer	0.00156	0.00156	CcSEcCtD
Zuclopenthixol—Anxiety—Doxorubicin—muscle cancer	0.00155	0.00155	CcSEcCtD
Zuclopenthixol—Paraesthesia—Methotrexate—muscle cancer	0.00155	0.00155	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.00155	0.00155	CcSEcCtD
Zuclopenthixol—Discomfort—Doxorubicin—muscle cancer	0.00154	0.00154	CcSEcCtD
Zuclopenthixol—Dyspnoea—Methotrexate—muscle cancer	0.00154	0.00154	CcSEcCtD
Zuclopenthixol—Somnolence—Methotrexate—muscle cancer	0.00153	0.00153	CcSEcCtD
Zuclopenthixol—Dry mouth—Doxorubicin—muscle cancer	0.00153	0.00153	CcSEcCtD
Zuclopenthixol—Dyspepsia—Methotrexate—muscle cancer	0.00152	0.00152	CcSEcCtD
Zuclopenthixol—Decreased appetite—Methotrexate—muscle cancer	0.0015	0.0015	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Doxorubicin—muscle cancer	0.00149	0.00149	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Methotrexate—muscle cancer	0.00149	0.00149	CcSEcCtD
Zuclopenthixol—Fatigue—Methotrexate—muscle cancer	0.00149	0.00149	CcSEcCtD
Zuclopenthixol—Pain—Methotrexate—muscle cancer	0.00148	0.00148	CcSEcCtD
Zuclopenthixol—Shock—Doxorubicin—muscle cancer	0.00147	0.00147	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Doxorubicin—muscle cancer	0.00147	0.00147	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Doxorubicin—muscle cancer	0.00146	0.00146	CcSEcCtD
Zuclopenthixol—Tachycardia—Doxorubicin—muscle cancer	0.00146	0.00146	CcSEcCtD
Zuclopenthixol—Skin disorder—Doxorubicin—muscle cancer	0.00145	0.00145	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Doxorubicin—muscle cancer	0.00145	0.00145	CcSEcCtD
Zuclopenthixol—Anorexia—Doxorubicin—muscle cancer	0.00142	0.00142	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Methotrexate—muscle cancer	0.00142	0.00142	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Methotrexate—muscle cancer	0.00141	0.00141	CcSEcCtD
Zuclopenthixol—Hypotension—Doxorubicin—muscle cancer	0.0014	0.0014	CcSEcCtD
Zuclopenthixol—Abdominal pain—Methotrexate—muscle cancer	0.00136	0.00136	CcSEcCtD
Zuclopenthixol—Body temperature increased—Methotrexate—muscle cancer	0.00136	0.00136	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.00136	0.00136	CcSEcCtD
Zuclopenthixol—Insomnia—Doxorubicin—muscle cancer	0.00135	0.00135	CcSEcCtD
Zuclopenthixol—Paraesthesia—Doxorubicin—muscle cancer	0.00134	0.00134	CcSEcCtD
Zuclopenthixol—Dyspnoea—Doxorubicin—muscle cancer	0.00133	0.00133	CcSEcCtD
Zuclopenthixol—Somnolence—Doxorubicin—muscle cancer	0.00133	0.00133	CcSEcCtD
Zuclopenthixol—Dyspepsia—Doxorubicin—muscle cancer	0.00132	0.00132	CcSEcCtD
Zuclopenthixol—Decreased appetite—Doxorubicin—muscle cancer	0.0013	0.0013	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.00129	0.00129	CcSEcCtD
Zuclopenthixol—Fatigue—Doxorubicin—muscle cancer	0.00129	0.00129	CcSEcCtD
Zuclopenthixol—Constipation—Doxorubicin—muscle cancer	0.00128	0.00128	CcSEcCtD
Zuclopenthixol—Pain—Doxorubicin—muscle cancer	0.00128	0.00128	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Methotrexate—muscle cancer	0.00127	0.00127	CcSEcCtD
Zuclopenthixol—Asthenia—Methotrexate—muscle cancer	0.00124	0.00124	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Doxorubicin—muscle cancer	0.00123	0.00123	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Doxorubicin—muscle cancer	0.00122	0.00122	CcSEcCtD
Zuclopenthixol—Pruritus—Methotrexate—muscle cancer	0.00122	0.00122	CcSEcCtD
Zuclopenthixol—Abdominal pain—Doxorubicin—muscle cancer	0.00118	0.00118	CcSEcCtD
Zuclopenthixol—Body temperature increased—Doxorubicin—muscle cancer	0.00118	0.00118	CcSEcCtD
Zuclopenthixol—Diarrhoea—Methotrexate—muscle cancer	0.00118	0.00118	CcSEcCtD
Zuclopenthixol—Dizziness—Methotrexate—muscle cancer	0.00114	0.00114	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Doxorubicin—muscle cancer	0.0011	0.0011	CcSEcCtD
Zuclopenthixol—Vomiting—Methotrexate—muscle cancer	0.0011	0.0011	CcSEcCtD
Zuclopenthixol—Rash—Methotrexate—muscle cancer	0.00109	0.00109	CcSEcCtD
Zuclopenthixol—Dermatitis—Methotrexate—muscle cancer	0.00109	0.00109	CcSEcCtD
Zuclopenthixol—Headache—Methotrexate—muscle cancer	0.00108	0.00108	CcSEcCtD
Zuclopenthixol—Asthenia—Doxorubicin—muscle cancer	0.00107	0.00107	CcSEcCtD
Zuclopenthixol—Pruritus—Doxorubicin—muscle cancer	0.00106	0.00106	CcSEcCtD
Zuclopenthixol—Nausea—Methotrexate—muscle cancer	0.00103	0.00103	CcSEcCtD
Zuclopenthixol—Diarrhoea—Doxorubicin—muscle cancer	0.00102	0.00102	CcSEcCtD
Zuclopenthixol—Dizziness—Doxorubicin—muscle cancer	0.000989	0.000989	CcSEcCtD
Zuclopenthixol—Vomiting—Doxorubicin—muscle cancer	0.00095	0.00095	CcSEcCtD
Zuclopenthixol—Rash—Doxorubicin—muscle cancer	0.000943	0.000943	CcSEcCtD
Zuclopenthixol—Dermatitis—Doxorubicin—muscle cancer	0.000942	0.000942	CcSEcCtD
Zuclopenthixol—Headache—Doxorubicin—muscle cancer	0.000936	0.000936	CcSEcCtD
Zuclopenthixol—Nausea—Doxorubicin—muscle cancer	0.000888	0.000888	CcSEcCtD
